Cargando…

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

PURPOSE: Mesenchymal–epithelial transition factor (MET) is expressed in gastric cancer and associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics of emibetuzumab, a bivalent monoclonal anti-MET antibody that blocks ligand-dependent and ligand-independent MET signa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakai, Daisuke, Chung, Hyun Cheol, Oh, Do-Youn, Park, Se Hoon, Kadowaki, Shigenori, Kim, Yeul Hong, Tsuji, Akihito, Komatsu, Yoshito, Kang, Yoon-Koo, Uenaka, Kazunori, Wijayawardana, Sameera R., Wacheck, Volker, Wang, Xuejing, Yamamura, Ayuko, Doi, Toshihiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5686250/ https://www.ncbi.nlm.nih.gov/pubmed/29071414 http://dx.doi.org/10.1007/s00280-017-3445-z

Ejemplares similares

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping
por: Yan, S. Betty, et al.
Publicado: (2017)

A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies
por: Yoh, Kiyotaka, et al.
Publicado: (2016)

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm
por: Sawaki, Akira, et al.
Publicado: (2017)

Improved glycemic control and reduced bodyweight with exenatide: A double‐blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2010)

Intra-Examiner and Inter-Examiner Reproducibility of Paraspinal Thermography
por: McCoy, Matthew, et al.
Publicado: (2011)

Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer
por: Kondo, Shunsuke, et al.
Publicado: (2020)

Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors
por: Shitara, Kohei, et al.
Publicado: (2020)

Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer
por: Komforti, Miglena, et al.
Publicado: (2022)

hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
por: Martinelli, Ilaria, et al.
Publicado: (2022)

Met in Urological Cancers
por: Miyata, Yasuyoshi, et al.
Publicado: (2014)

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

The Phase Modulating Micro-Mover Based on the MHD/MET System in the Reference Arm of the Scanning Interferometer
por: Kalenkov, Sergey, et al.
Publicado: (2022)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2019)

An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)
por: Kawakami, Hisato, et al.
Publicado: (2021)

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
por: Sawaki, Akira, et al.
Publicado: (2009)

HGF–Met Pathway in Regeneration and Drug Discovery
por: Matsumoto, Kunio, et al.
Publicado: (2014)

Characterization of Mouse Monoclonal Antibody B1.4 Reactive with Human Invasive Bladder Cancer and Some Other Malignant Tumors but Not with Normal Urinary Epithelium
por: Saiki, Shigeru, et al.
Publicado: (1994)

Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
por: Doi, Toshihiko, et al.
Publicado: (2010)

A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer
por: Yamaguchi, Kazuhisa, et al.
Publicado: (2015)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma
por: Yin, Yanxin, et al.
Publicado: (2019)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

The Blocking of c-Met Signaling Induces Apoptosis through the Increase of p53 Protein in Lung Cancer
por: Jung, Hae-Yun, et al.
Publicado: (2012)

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
por: Mishima, Saori, et al.
Publicado: (2019)

Characterizing the roles of Met31 and Met32 in coordinating Met4-activated transcription in the absence of Met30
por: Carrillo, Emilio, et al.
Publicado: (2012)

Cyclic Peptide-Based Biologics Regulating HGF-MET
por: Sato, Hiroki, et al.
Publicado: (2020)

MET-9 LEPTOMENINGEAL CARCINOMATOSIS ~ ITS' ASSOCIATION WITH MOLECULAR AND PATHOLOGICAL SUBTYPES~
por: Iuchi, Toshihiko, et al.
Publicado: (2022)

Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
por: Yoshino, Takayuki, et al.
Publicado: (2014)

When COVID-19 Met Families Living in Armed-Conflict Zones: The Importance of Maternal Trauma and Child Self-Regulation
por: Levavi, Kinneret, et al.
Publicado: (2022)

A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Molecular tools in drug research — translational medicine
por: Eder, Sandra, et al.
Publicado: (2011)

Fecal microbiota in patients with a stoma decreases anaerobic bacteria and alters taxonomic and functional diversities
por: Sakai, Shunsuke A., et al.
Publicado: (2022)

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes
por: Inagaki, Nobuya, et al.
Publicado: (2011)

Artificial human Met agonists based on macrocycle scaffolds
por: Ito, Kenichiro, et al.
Publicado: (2015)

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature
por: Honda, Kazunori, et al.
Publicado: (2017)

Critical Role of MetR/MetB/MetC/MetX in Cysteine and Methionine Metabolism, Fungal Development, and Virulence of Alternaria alternata
por: Gai, Yunpeng, et al.
Publicado: (2021)

Strangulated interstitial interparietal hernia following lower segment caesarean section: a case report
por: Garrett, Celine, et al.
Publicado: (2023)

Inhibition of B6RV2 Leukemia Growth by Immunization with Purified Unique Antigen
por: Uenaka, Akiko, et al.
Publicado: (1992)

Cannot write session to /tmp/vufind_sessions/sess_jek9mpi00gjbropvv9q4ok2kla